New prospectives of prostate cancer gene therapy

Molecular targets and animal models

Chia Ling Hsieh, Leland W K Chung

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Prostate cancer is the most common cancer and the second leading cause of cancer-related death among North American men. The low cure rate for prostate cancer is associated with the fact that many patients have metastatic disease at the time of disease presentation. Currently available therapeutic modalities for prostate cancer, such as surgery, radiation, hormone therapy, and chemotherapy, have failed to cure patients because these therapies are not sufficiently tumor-specific, resulting in dose-limiting toxicity. Therefore, gene therapy may offer great promise in this regard. In this article, we summarize current advances in gene therapy technologies for the treatment of cancer in general, and future prospects for treatment of human prostate cancer metastasis. We specifically emphasize current studies for improvement, both in the efficiency and the specificity of viral and nonviral vectors, and restricted transgene expression in tumors, to achieve selective targeting with minimized host organ toxicity, based on the molecular understanding of potential regulatory differences between normal and tumor cells. Cell and animal models used to study prostate cancer growth, invasion, and metastasis, and their usefulness in preclinical evaluation of therapeutic vectors in the treatment of protate cancer skeletal metastasis are also discussed.

Original languageEnglish
Pages (from-to)77-120
Number of pages44
JournalCritical Reviews in Eukaryotic Gene Expression
Volume11
Issue number1-3
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Molecular Models
Neoplasm Genes
Genetic Therapy
Prostatic Neoplasms
Animal Models
Neoplasms
Neoplasm Metastasis
Therapeutics
Second Primary Neoplasms
Transgenes
Radiotherapy
Hormones
Technology
Drug Therapy
Growth

Keywords

  • Bone matrix proteins in prostate cancer
  • Bystander cell-kill
  • Cancer metastasis
  • Gene therapy for prostate cancer
  • Molecular targeting
  • Stromal-epithelial interaction
  • Tissue-specific transgene expression

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

New prospectives of prostate cancer gene therapy : Molecular targets and animal models. / Hsieh, Chia Ling; Chung, Leland W K.

In: Critical Reviews in Eukaryotic Gene Expression, Vol. 11, No. 1-3, 2001, p. 77-120.

Research output: Contribution to journalArticle

@article{6c25c411188e446188af73aa60eeb623,
title = "New prospectives of prostate cancer gene therapy: Molecular targets and animal models",
abstract = "Prostate cancer is the most common cancer and the second leading cause of cancer-related death among North American men. The low cure rate for prostate cancer is associated with the fact that many patients have metastatic disease at the time of disease presentation. Currently available therapeutic modalities for prostate cancer, such as surgery, radiation, hormone therapy, and chemotherapy, have failed to cure patients because these therapies are not sufficiently tumor-specific, resulting in dose-limiting toxicity. Therefore, gene therapy may offer great promise in this regard. In this article, we summarize current advances in gene therapy technologies for the treatment of cancer in general, and future prospects for treatment of human prostate cancer metastasis. We specifically emphasize current studies for improvement, both in the efficiency and the specificity of viral and nonviral vectors, and restricted transgene expression in tumors, to achieve selective targeting with minimized host organ toxicity, based on the molecular understanding of potential regulatory differences between normal and tumor cells. Cell and animal models used to study prostate cancer growth, invasion, and metastasis, and their usefulness in preclinical evaluation of therapeutic vectors in the treatment of protate cancer skeletal metastasis are also discussed.",
keywords = "Bone matrix proteins in prostate cancer, Bystander cell-kill, Cancer metastasis, Gene therapy for prostate cancer, Molecular targeting, Stromal-epithelial interaction, Tissue-specific transgene expression",
author = "Hsieh, {Chia Ling} and Chung, {Leland W K}",
year = "2001",
language = "English",
volume = "11",
pages = "77--120",
journal = "Critical Reviews in Eukaryotic Gene Expression",
issn = "1045-4403",
publisher = "Begell House Inc.",
number = "1-3",

}

TY - JOUR

T1 - New prospectives of prostate cancer gene therapy

T2 - Molecular targets and animal models

AU - Hsieh, Chia Ling

AU - Chung, Leland W K

PY - 2001

Y1 - 2001

N2 - Prostate cancer is the most common cancer and the second leading cause of cancer-related death among North American men. The low cure rate for prostate cancer is associated with the fact that many patients have metastatic disease at the time of disease presentation. Currently available therapeutic modalities for prostate cancer, such as surgery, radiation, hormone therapy, and chemotherapy, have failed to cure patients because these therapies are not sufficiently tumor-specific, resulting in dose-limiting toxicity. Therefore, gene therapy may offer great promise in this regard. In this article, we summarize current advances in gene therapy technologies for the treatment of cancer in general, and future prospects for treatment of human prostate cancer metastasis. We specifically emphasize current studies for improvement, both in the efficiency and the specificity of viral and nonviral vectors, and restricted transgene expression in tumors, to achieve selective targeting with minimized host organ toxicity, based on the molecular understanding of potential regulatory differences between normal and tumor cells. Cell and animal models used to study prostate cancer growth, invasion, and metastasis, and their usefulness in preclinical evaluation of therapeutic vectors in the treatment of protate cancer skeletal metastasis are also discussed.

AB - Prostate cancer is the most common cancer and the second leading cause of cancer-related death among North American men. The low cure rate for prostate cancer is associated with the fact that many patients have metastatic disease at the time of disease presentation. Currently available therapeutic modalities for prostate cancer, such as surgery, radiation, hormone therapy, and chemotherapy, have failed to cure patients because these therapies are not sufficiently tumor-specific, resulting in dose-limiting toxicity. Therefore, gene therapy may offer great promise in this regard. In this article, we summarize current advances in gene therapy technologies for the treatment of cancer in general, and future prospects for treatment of human prostate cancer metastasis. We specifically emphasize current studies for improvement, both in the efficiency and the specificity of viral and nonviral vectors, and restricted transgene expression in tumors, to achieve selective targeting with minimized host organ toxicity, based on the molecular understanding of potential regulatory differences between normal and tumor cells. Cell and animal models used to study prostate cancer growth, invasion, and metastasis, and their usefulness in preclinical evaluation of therapeutic vectors in the treatment of protate cancer skeletal metastasis are also discussed.

KW - Bone matrix proteins in prostate cancer

KW - Bystander cell-kill

KW - Cancer metastasis

KW - Gene therapy for prostate cancer

KW - Molecular targeting

KW - Stromal-epithelial interaction

KW - Tissue-specific transgene expression

UR - http://www.scopus.com/inward/record.url?scp=0034772315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034772315&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 77

EP - 120

JO - Critical Reviews in Eukaryotic Gene Expression

JF - Critical Reviews in Eukaryotic Gene Expression

SN - 1045-4403

IS - 1-3

ER -